Recilisib

SKU: orb1308768

Description

Recilisib (ON 01210) is a small molecule radioprotectant that functions by activating the PI3K/AKT signaling pathway. It has demonstrated protective effects in cellular (in vitro) and animal (in vivo) models against radiation-induced damage, supporting its research in radiation biology and oncology.

Research Area

Signal Transduction

Key Properties

• CAS Number: 334969-03-8
• MW: 336.79
• Purity: 99.84% (May vary between batches)
• Formula: C₁₆H₁₃ClO₄S
• SMILES: OC(=O)c1ccc(\C=C\S(=O)(=O)Cc2ccc(Cl)cc2)cc1
• Target: Akt,PI3K
• Solubility: 10% DMSO+90% Corn Oil:2.5 mg/mL (7.42 mM);DMSO:50 mg/mL (148.46 mM)

Bioactivity

• In Vivo:
  the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice significantly increased by Recilisib Sodium. Recilisib Sodium in combination with radiation reduces CFU numbers in mice, but the Recilisib Sodium-treated mice consistently retain a capability to form differentiated colonies. Recilisib Sodium treated mice have a progenitor cell population that is never completely depleted by radiation exposure.
• In Vitro:
  Recilisib Sodium increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib Sodium treatment in combination with radiation alters the MAPK signaling pathway.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Recilisib, PI3K, PKB, Protein kinase B, Phosphoinositide 3-kinase, ON01210, ON-01210, ON 01210, inhibit, Inhibitor, Ex-RAD, Akt

Compound Identifiers

PubChem CID

9884220